Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human prothrombin complex concentrate in hemophilia B
CTR20170571Phase 3Completed
- Sponsor
- China Resources Boya Bio-pharmaceutical Group
- Start
- Jun 2017
- Modality
- Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of balfaxar in hemophilia B (HB), Congenital Prothrombin Deficiency, congenital factor VII deficiency, factor X deficiency (FXD), acquired prothrombin deficiency, sponsored by China Resources Boya Bio-pharmaceutical Group. Started Jun 2017; status: completed.
02
Drugs
balfaxar
03
Conditions
hemophilia B (HB)Congenital Prothrombin Deficiencycongenital factor VII deficiencyfactor X deficiency (FXD)acquired prothrombin deficiency
Beyond the preview
Go deeper on CTR20170571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170571.